{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:00:52Z","timestamp":1781650852489,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM135028"],"award-info":[{"award-number":["T32GM135028"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["R01CA240589"],"award-info":[{"award-number":["R01CA240589"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02286-9","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:34:02Z","timestamp":1777106042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD8 immunoPET imaging to stratify response and guide combination immunotherapy and radiation in triple negative breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Patrick N.","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe T.","family":"DeMellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon E.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Gallegos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameer","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Moye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mascioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Willey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna G.","family":"Sorace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"3","key":"2286_CR1","first-page":"51","volume":"4","author":"T Bhattacharyya","year":"2016","unstructured":"Bhattacharyya T, et al. Immunological interactions in radiotherapy-opening a new window of opportunity. Ann Transl Med. 2016;4(3):51.","journal-title":"Ann Transl Med"},{"issue":"4","key":"2286_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687\u201392.","journal-title":"Clin Cancer Res"},{"key":"2286_CR3","doi-asserted-by":"crossref","unstructured":"Reeves KM et al. 18F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition. Clin Cancer Res, 2021.","DOI":"10.1158\/1078-0432.CCR-21-2394"},{"key":"2286_CR4","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.2147\/IJN.S140462","volume":"13","author":"K Graham","year":"2018","unstructured":"Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomed. 2018;13:6049\u201358.","journal-title":"Int J Nanomed"},{"key":"2286_CR5","doi-asserted-by":"publisher","first-page":"610303","DOI":"10.3389\/fonc.2021.610303","volume":"11","author":"V Salemme","year":"2021","unstructured":"Salemme V, et al. The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Front Oncol. 2021;11:610303.","journal-title":"Front Oncol"},{"issue":"1","key":"2286_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41523-022-00476-0","volume":"8","author":"V Petrosyan","year":"2022","unstructured":"Petrosyan V, et al. Immunologically cold triple negative breast cancers engraft at a higher rate in patient derived xenografts. NPJ Breast Cancer. 2022;8(1):104.","journal-title":"NPJ Breast Cancer"},{"issue":"48","key":"2286_CR7","doi-asserted-by":"publisher","first-page":"26296","DOI":"10.1021\/jacs.3c09472","volume":"145","author":"X Liu","year":"2023","unstructured":"Liu X, et al. Transforming Intratumor Bacteria into Immunopotentiators to Reverse Cold Tumors for Enhanced Immuno-chemodynamic Therapy of Triple-Negative Breast Cancer. J Am Chem Soc. 2023;145(48):26296\u2013307.","journal-title":"J Am Chem Soc"},{"key":"2286_CR8","doi-asserted-by":"crossref","unstructured":"Toulany M. Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response. Genes (Basel), 2019. 10(1).","DOI":"10.3390\/genes10010025"},{"issue":"1\u20132","key":"2286_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.canrad.2021.11.013","volume":"26","author":"C Hennequin","year":"2022","unstructured":"Hennequin C, et al. Radiotherapy of breast cancer. Cancer Radiother. 2022;26(1\u20132):221\u201330.","journal-title":"Cancer Radiother"},{"key":"2286_CR10","doi-asserted-by":"crossref","unstructured":"Song PN et al. Modulation of the Tumor Microenvironment with Trastuzumab Enables Radiosensitization in HER2\u2009+\u2009Breast Cancer. Cancers (Basel), 2022. 14(4).","DOI":"10.3390\/cancers14041015"},{"key":"2286_CR11","doi-asserted-by":"publisher","first-page":"905437","DOI":"10.3389\/fsurg.2022.905437","volume":"9","author":"B Li","year":"2022","unstructured":"Li B, et al. Evaluation of adjuvant therapy for T1-2N1miM0 breast cancer without further axillary lymph node dissection. Front Surg. 2022;9:905437.","journal-title":"Front Surg"},{"issue":"1","key":"2286_CR12","first-page":"25","volume":"1","author":"D Mampre","year":"2022","unstructured":"Mampre D, et al. Treatment of breast cancer brain metastases: radiotherapy and emerging preclinical approaches. Diagn Ther. 2022;1(1):25\u201338.","journal-title":"Diagn Ther"},{"issue":"7","key":"2286_CR13","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1172\/JCI69219","volume":"123","author":"A Kalbasi","year":"2013","unstructured":"Kalbasi A, et al. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013;123(7):2756\u201363.","journal-title":"J Clin Invest"},{"issue":"14","key":"2286_CR14","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao S, et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017;23(14):3711\u201320.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2286_CR15","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.trecan.2016.09.007","volume":"2","author":"W Jiang","year":"2016","unstructured":"Jiang W, et al. Immune Priming of the Tumor Microenvironment by Radiation. Trends Cancer. 2016;2(11):638\u201345.","journal-title":"Trends Cancer"},{"key":"2286_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fphar.2018.00185","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y, et al. Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Front Pharmacol. 2018;9:185.","journal-title":"Front Pharmacol"},{"key":"2286_CR17","doi-asserted-by":"crossref","unstructured":"Zhang Y et al. A novel translational PET imaging approach to quantifying abscopal immune activation following targeted radiotherapy and checkpoint blockade. Int J Radiat Oncol Biol Phys, 2024.","DOI":"10.1016\/j.ijrobp.2023.12.047"},{"issue":"4","key":"2286_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.bj.2017.06.003","volume":"40","author":"Q Wu","year":"2017","unstructured":"Wu Q, et al. Macrophage biology plays a central role during ionizing radiation-elicited tumor response. Biomed J. 2017;40(4):200\u201311.","journal-title":"Biomed J"},{"key":"2286_CR19","doi-asserted-by":"publisher","first-page":"670464","DOI":"10.3389\/fonc.2021.670464","volume":"11","author":"C Zhang","year":"2021","unstructured":"Zhang C, et al. Radiotherapy and Cytokine Storm: Risk and Mechanism. Front Oncol. 2021;11:670464.","journal-title":"Front Oncol"},{"issue":"8","key":"2286_CR20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","volume":"39","author":"ME Rodriguez-Ruiz","year":"2018","unstructured":"Rodriguez-Ruiz ME, et al. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. Trends Immunol. 2018;39(8):644\u201355.","journal-title":"Trends Immunol"},{"issue":"2","key":"2286_CR21","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41577-021-00568-1","volume":"22","author":"UM Cytlak","year":"2022","unstructured":"Cytlak UM, et al. Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. Nat Rev Immunol. 2022;22(2):124\u201338.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2286_CR22","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1038\/s41598-018-30417-6","volume":"8","author":"HY Chen","year":"2018","unstructured":"Chen HY, et al. Inhibiting the CD8(+) T cell infiltration in the tumor microenvironment after radiotherapy is an important mechanism of radioresistance. Sci Rep. 2018;8(1):11934.","journal-title":"Sci Rep"},{"key":"2286_CR23","doi-asserted-by":"crossref","unstructured":"Jones KI et al. Radiation combined with macrophage depletion promotes adaptive immunity and potentiates checkpoint blockade. EMBO Mol Med, 2018. 10(12).","DOI":"10.15252\/emmm.201809342"},{"issue":"2","key":"2286_CR24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1309\/AJCPIXUYDVZ0RZ3G","volume":"144","author":"HJ Lee","year":"2015","unstructured":"Lee HJ, et al. Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. Am J Clin Pathol. 2015;144(2):278\u201388.","journal-title":"Am J Clin Pathol"},{"issue":"64","key":"2286_CR25","doi-asserted-by":"publisher","first-page":"eabj8825","DOI":"10.1126\/sciimmunol.abj8825","volume":"6","author":"RA Watson","year":"2021","unstructured":"Watson RA, et al. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8(+) T cell clone size and cytotoxicity. Sci Immunol. 2021;6(64):eabj8825.","journal-title":"Sci Immunol"},{"issue":"9","key":"2286_CR26","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1073\/pnas.1817652116","volume":"116","author":"X Li","year":"2019","unstructured":"Li X, et al. Infiltration of CD8(+) T cells into tumor cell clusters in triple-negative breast cancer. Proc Natl Acad Sci U S A. 2019;116(9):3678\u201387.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2286_CR27","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1007\/s00432-019-03036-5","volume":"145","author":"H Vihervuori","year":"2019","unstructured":"Vihervuori H, et al. Tumor-infiltrating lymphocytes and CD8(+) T cells predict survival of triple-negative breast cancer. J Cancer Res Clin Oncol. 2019;145(12):3105\u201314.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2286_CR28","doi-asserted-by":"crossref","unstructured":"Oshi M et al. CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer. Int J Mol Sci, 2020. 21(18).","DOI":"10.3390\/ijms21186968"},{"key":"2286_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4137\/BMI.S2185","volume":"5","author":"LL Matos","year":"2010","unstructured":"Matos LL, et al. Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark Insights. 2010;5:9\u201320.","journal-title":"Biomark Insights"},{"issue":"6","key":"2286_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.4132\/jptm.2016.08.08","volume":"50","author":"SW Kim","year":"2016","unstructured":"Kim SW, Roh J, Park CS. Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips. J Pathol Transl Med. 2016;50(6):411\u20138.","journal-title":"J Pathol Transl Med"},{"issue":"8","key":"2286_CR31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/NEN.0b013e31822713f0","volume":"70","author":"M Preusser","year":"2011","unstructured":"Preusser M, et al. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol. 2011;70(8):715\u201323.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"2286_CR32","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1021\/acs.molpharmaceut.2c00977","volume":"20","author":"CC Parker","year":"2023","unstructured":"Parker CC, et al. Evaluation of a CD206-Targeted Peptide for PET Imaging of Macrophages in Syngeneic Mouse Models of Cancer. Mol Pharm. 2023;20(5):2415\u201325.","journal-title":"Mol Pharm"},{"issue":"9","key":"2286_CR33","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1158\/0008-5472.CAN-16-3346","volume":"77","author":"BM Larimer","year":"2017","unstructured":"Larimer BM, et al. Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Res. 2017;77(9):2318\u201327.","journal-title":"Cancer Res"},{"issue":"1","key":"2286_CR34","doi-asserted-by":"publisher","first-page":"15384","DOI":"10.1038\/s41598-021-94887-x","volume":"11","author":"BB Kasten","year":"2021","unstructured":"Kasten BB, et al. Positron emission tomography imaging with (89)Zr-labeled anti-CD8 cys-diabody reveals CD8(+) cell infiltration during oncolytic virus therapy in a glioma murine model. Sci Rep. 2021;11(1):15384.","journal-title":"Sci Rep"},{"issue":"12","key":"2286_CR35","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch F, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24(12):1852\u20138.","journal-title":"Nat Med"},{"key":"2286_CR36","doi-asserted-by":"crossref","unstructured":"Massicano AVF et al. [(89)Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models. Cancers (Basel), 2023. 15(10).","DOI":"10.3390\/cancers15102708"},{"issue":"3","key":"2286_CR37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.7150\/thno.89206","volume":"14","author":"CA Gallegos","year":"2024","unstructured":"Gallegos CA, et al. [(89)Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models. Theranostics. 2024;14(3):911\u201323.","journal-title":"Theranostics"},{"issue":"1","key":"2286_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/0008-5472.CAN-15-1707","volume":"76","author":"R Tavare","year":"2016","unstructured":"Tavare R, et al. An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Cancer Res. 2016;76(1):73\u201382.","journal-title":"Cancer Res"},{"issue":"4","key":"2286_CR39","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s11307-020-01481-0","volume":"22","author":"LK Kristensen","year":"2020","unstructured":"Kristensen LK, et al. Monitoring CD8a(+) T Cell Responses to Radiotherapy and CTLA-4 Blockade Using [(64)Cu]NOTA-CD8a PET Imaging. Mol Imaging Biol. 2020;22(4):1021\u201330.","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"2286_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13058-024-01844-3","volume":"26","author":"Y Lu","year":"2024","unstructured":"Lu Y, et al. Evaluating the immunologically cold tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4\u2009+\u2009and CD8\u2009+\u2009T cells in breast cancer mouse models. Breast Cancer Res. 2024;26(1):104.","journal-title":"Breast Cancer Res"},{"key":"2286_CR41","doi-asserted-by":"crossref","unstructured":"Lu Y et al. Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy. Cancers (Basel), 2026. 18(6).","DOI":"10.3390\/cancers18060997"},{"issue":"1","key":"2286_CR42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40425-018-0401-3","volume":"6","author":"G Xie","year":"2018","unstructured":"Xie G, et al. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy. J Immunother Cancer. 2018;6(1):88.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2286_CR43","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1038\/s41598-023-29925-x","volume":"13","author":"NFR Sham","year":"2023","unstructured":"Sham NFR, et al. Acquired radioresistance in EMT6 mouse mammary carcinoma cell line is mediated by CTLA-4 and PD-1 through JAK\/STAT\/PI3K pathway. Sci Rep. 2023;13(1):3108.","journal-title":"Sci Rep"},{"issue":"1","key":"2286_CR44","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/ijms15010927","volume":"15","author":"B Park","year":"2014","unstructured":"Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci. 2014;15(1):927\u201343.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2286_CR45","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1111\/bcp.14351","volume":"86","author":"V Gomez","year":"2020","unstructured":"Gomez V, et al. Radiation therapy and the innate immune response: Clinical implications for immunotherapy approaches. Br J Clin Pharmacol. 2020;86(9):1726\u201335.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2286_CR46","doi-asserted-by":"publisher","first-page":"155932582092674","DOI":"10.1177\/1559325820926744","volume":"18","author":"S Pan","year":"2020","unstructured":"Pan S, et al. Radiation Exposure-Induced Changes in the Immune Cells and Immune Factors of Mice With or Without Primary Lung Tumor. Dose Response. 2020;18(2):1559325820926744.","journal-title":"Dose Response"},{"issue":"3","key":"2286_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00262-013-1506-7","volume":"63","author":"JY Lim","year":"2014","unstructured":"Lim JY, et al. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother. 2014;63(3):259\u201371.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2286_CR48","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4049\/jimmunol.1200563","volume":"189","author":"A Gupta","year":"2012","unstructured":"Gupta A, et al. Radiotherapy promotes tumor-specific effector CD8\u2009+\u2009T cells via dendritic cell activation. J Immunol. 2012;189(2):558\u201366.","journal-title":"J Immunol"},{"issue":"10","key":"2286_CR49","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","volume":"14","author":"S Liu","year":"2023","unstructured":"Liu S, et al. Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity. Cell Death Dis. 2023;14(10):679.","journal-title":"Cell Death Dis"},{"key":"2286_CR50","doi-asserted-by":"crossref","unstructured":"Luque M et al. Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. Cancers (Basel), 2022. 14(24).","DOI":"10.3390\/cancers14246034"},{"issue":"1","key":"2286_CR51","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8(1):156.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2286_CR52","doi-asserted-by":"publisher","first-page":"e0004","DOI":"10.5041\/RMMJ.10179","volume":"6","author":"K Perica","year":"2015","unstructured":"Perica K, et al. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J. 2015;6(1):e0004.","journal-title":"Rambam Maimonides Med J"},{"key":"2286_CR53","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.","journal-title":"Nat Commun"},{"key":"2286_CR54","doi-asserted-by":"crossref","unstructured":"Napier TS et al. Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer. Pharmaceutics, 2022. 14(2).","DOI":"10.3390\/pharmaceutics14020440"},{"key":"2286_CR55","doi-asserted-by":"crossref","unstructured":"Napier TS et al. Molecular Imaging of Oxygenation Changes during Immunotherapy in Combination with Paclitaxel in Triple Negative Breast Cancer. Biomedicines, 2023. 11(1).","DOI":"10.3390\/biomedicines11010125"},{"issue":"17","key":"2286_CR56","doi-asserted-by":"publisher","first-page":"eade0625","DOI":"10.1126\/sciadv.ade0625","volume":"9","author":"K Wu","year":"2023","unstructured":"Wu K, et al. Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence. Sci Adv. 2023;9(17):eade0625.","journal-title":"Sci Adv"},{"key":"2286_CR57","doi-asserted-by":"publisher","first-page":"101405","DOI":"10.1016\/j.tranon.2022.101405","volume":"20","author":"T Rupp","year":"2022","unstructured":"Rupp T, et al. Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response. Transl Oncol. 2022;20:101405.","journal-title":"Transl Oncol"},{"issue":"1","key":"2286_CR58","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1038\/s41467-023-40844-3","volume":"14","author":"NP Rudqvist","year":"2023","unstructured":"Rudqvist NP, et al. Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors. Nat Commun. 2023;14(1):5146.","journal-title":"Nat Commun"},{"issue":"1","key":"2286_CR59","doi-asserted-by":"publisher","first-page":"56","DOI":"10.7861\/clinmed.2022-0589","volume":"23","author":"P Mahalingam","year":"2023","unstructured":"Mahalingam P, Newsom-Davis T. Cancer immunotherapy and the management of side effects. Clin Med (Lond). 2023;23(1):56\u201360.","journal-title":"Clin Med (Lond)"},{"key":"2286_CR60","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-3-319-53156-4_8","volume":"995","author":"N Abdel-Wahab","year":"2017","unstructured":"Abdel-Wahab N, Alshawa A, Suarez-Almazor ME. Adverse Events in Cancer Immunotherapy. Adv Exp Med Biol. 2017;995:155\u201374.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"2286_CR61","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5306\/wjco.v12.i3.150","volume":"12","author":"A Kichloo","year":"2021","unstructured":"Kichloo A, et al. Systemic adverse effects and toxicities associated with immunotherapy: A review. World J Clin Oncol. 2021;12(3):150\u201363.","journal-title":"World J Clin Oncol"},{"issue":"11","key":"2286_CR62","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1158\/1535-7163.MCT-22-0010","volume":"21","author":"H Wang","year":"2022","unstructured":"Wang H, et al. Systemic Checkpoint Blockade by PD-L1 Single-Chain Antibody Confers Potent Antitumor Immunity and Long-term Survival. Mol Cancer Ther. 2022;21(11):1710\u201321.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2286_CR63","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/BF00121199","volume":"1","author":"P Nanni","year":"1983","unstructured":"Nanni P, et al. TS\/A: a new metastasizing cell line from a BALB\/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis. 1983;1(4):373\u201380.","journal-title":"Clin Exp Metastasis"},{"issue":"765","key":"2286_CR64","doi-asserted-by":"publisher","first-page":"eadk0642","DOI":"10.1126\/scitranslmed.adk0642","volume":"16","author":"JC Jagodinsky","year":"2024","unstructured":"Jagodinsky JC, et al. Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade. Sci Transl Med. 2024;16(765):eadk0642.","journal-title":"Sci Transl Med"},{"key":"2286_CR65","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3389\/fneur.2017.00748","volume":"8","author":"J Mann","year":"2017","unstructured":"Mann J, et al. Advances in Radiotherapy for Glioblastoma. Front Neurol. 2017;8:748.","journal-title":"Front Neurol"},{"issue":"2","key":"2286_CR66","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1055\/s-0030-1255330","volume":"24","author":"SA Yeh","year":"2010","unstructured":"Yeh SA. Radiotherapy for head and neck cancer. Semin Plast Surg. 2010;24(2):127\u201336.","journal-title":"Semin Plast Surg"},{"issue":"10","key":"2286_CR67","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3748\/wjg.v12.i10.1511","volume":"12","author":"L Hazard","year":"2006","unstructured":"Hazard L, O\u2019Connor J, Scaife C. Role of radiation therapy in gastric adenocarcinoma. World J Gastroenterol. 2006;12(10):1511\u201320.","journal-title":"World J Gastroenterol"},{"key":"2286_CR68","doi-asserted-by":"crossref","unstructured":"Patel RB et al. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med, 2021. 13(602).","DOI":"10.1126\/scitranslmed.abb3631"},{"key":"2286_CR69","doi-asserted-by":"crossref","unstructured":"Kerr CP et al. Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment. Pharmaceutics, 2022. 15(1).","DOI":"10.3390\/pharmaceutics15010128"},{"issue":"4","key":"2286_CR70","doi-asserted-by":"publisher","first-page":"e0277714","DOI":"10.1371\/journal.pone.0277714","volume":"18","author":"M Llano-Leon","year":"2023","unstructured":"Llano-Leon M, et al. Effect of neoadjuvant chemotherapy on tumor immune infiltration in breast cancer patients: Systematic review and meta-analysis. PLoS ONE. 2023;18(4):e0277714.","journal-title":"PLoS ONE"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02286-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02286-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02286-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:43:54Z","timestamp":1781649834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02286-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2286"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02286-9","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}